Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...
This article was published on June 2, 2025, at 10:26 a.m. on the ChosunBiz MoneyMove site. Contentree JoongAng is pushing to sell its subsidiary SLL JoongAng's management rights. Initially, SLL ...
Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback